- Status:
- Topic prioritisation
- Technology type:
- Medicine
- Decision:
- Not selected
- Prioritisation programme:
- Medicines evaluation
- Rationale:
The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers have concluded that the clear rationale to not evaluate this product is due commissioning arrangements already being in place for peginterferon alfa-2a via NHS England for this indication. Therefore, a NICE evaluation is not anticipated to add any further value. Please see eligibility criteria within the prioritisation manual for further information.
- ID number:
- 12325
Project Team
- Project lead
- Danielle Lees
Email enquiries
If you have any queries please email topic.selection@nice.org.uk
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 04 February 2026 | Prioritisation board meeting |
For further information on how we select topics for development, please see our page about topic prioritisation